(Reuters) – Ocugen Inc on Thursday said it would file for full U.S. approval of its COVID-19 vaccine candidate, COVAXIN, without pursuing an emergency use authorization.
(Reporting by Amruta Khandekar; Editing by Vinay Dwivedi)
Ocugen to file for full U.S. approval of COVID-19 vaccine
Jun 10, 2021 | 7:45 AM
